Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation

Transplantation

Volumn 63, Issue 3, 1997, Pages 476-478

  Rosen, Hugo R ^a   Benner, Kent G ^a   Flora, Kenneth D ^a   Rabkin, John M ^a,b   Orloff, Susan L ^a,b   Olyaei, Ali ^a   Chou, Sunwen ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; METHYLPREDNISOLONE; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ALAGILLE SYNDROME; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS ISOLATION;

ADOLESCENT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, MICROBIAL; FOSCARNET; GANCICLOVIR; HUMANS; LIVER TRANSPLANTATION; MALE;

EID: 0031037245     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199702150-00026     Document Type: Article

References (9)

1. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
2. McCarthy JM, Karim M, Kruegar H, Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993; 55: 1277.
3. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69.
4. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320: 289.
5. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716.
6. Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993; 168: 332.
7. Chou S, Erice A, Jordan MC, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995; 171: 576.
8. Drew WL, Anderson R, Lang W, Miner RC, Davis G, Lalezari J. Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 289.
9. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995; 172: 239.